Reason and reality-identifying barriers to patient enrolment for clinical trials in invasive candidiasis.

Authors:
Sprute R; Grothe JH; Heringer S; Cornely OA.

Journal:
J Antimicrob Chemother

Publication Year: 2022

DOI:
10.1093/jac/dkac344

PMCID:
PMC9704424

PMID:
36214051

View on PubMed View on PMC View Publisher
Journal Information

Full Title: J Antimicrob Chemother

Abbreviation: J Antimicrob Chemother

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Anti-Infective Agents

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
A detailed characterization of drug resistance during darunavir/ritonavir monotherapy highlights a …
Abdullahi A; Diaz AG; Fopoussi OM and 5 more (2024) - Transparency Score: 2/6
Antimicrobial use and combination of resistance phenotypes in bacteraemic Escherichia coli in prima…
Hosaka Y; Muraki Y; Kajihara T and 6 more (2024) - Transparency Score: 2/6
A pharmacy-led sore throat test and treat (STTT) service: antigen testing and antibiotic supply rat…
Mantzourani E; Ahmed H; Evans A and 2 more (2024) - Transparency Score: 2/6
Bedaquiline for treatment of non-tuberculous mycobacteria (NTM): a systematic review and meta-analy…
Omar S; Whitfield MG; Nolan MB and 4 more (2024) - Transparency Score: 4/6
Clostridium neonatale antimicrobial susceptibility, genetic resistance determinants, and genotyping…
Ferraris L; Delannoy J; Mazuet C and 4 more (2024) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
2/6
33.3% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
COI Disclosure
Evidence found in paper:

"Funding This study was carried out as part of our routine work."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025